Cancer Vaccines
BEC2 Enters Phase III Small Cell Lung Carcinoma Clinical Trials
Published in Cancer Weekly, June 1st, 1998
Merck KGaA, Darmstadt, Germany, is ImClone's corporate partner in the development of BEC2. The Phase III trial evaluates the effect of BEC2 in approximately 800 patients with small cell lung carcinoma.
"The initiation of ImClone's first Phase III trial marks a milestone for the company," commented Harlan W. Waksal, M.D., ImClone Systems. "This is the most advanced lung cancer vaccine study and one of the largest studies of any type of cancer vaccine. We are encouraged by our results from previous tests and look...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (1998-06-01)
More Articles from Cancer Weekly
- Conference Coverage (ASCO)
Liposomal Doxorubicin Tested In AIDS-Related Kaposi's Sarcoma - Conference Coverage (ASCO)
Adenoviral-Mediated p53 Gene Therapy Safely Administered to Patients - Conference Coverage (ASCO)
Canarypox Vector Explored as Immunotherapy Vehicle - Conference Coverage (ASCO)
PBPC Transplantation Supports Dose Intensive Chemo in Children - Conference Coverage (ASCO)
Risks Associated with Chemotherapy-Based Transfusion Requirements are Quantified - Conference Coverage (ASCO)
The Exploration Continues, Canarypox Vector Safely Administers GM-CSF, Too - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
